Alps Group Inc
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Seng Kong Tham
- Full Time Employees
- 2
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Unit E-18-01 & E-18-02, Level 18, Icon Tower (East), No. 1, Jalan 1/68F, Off Jalan Tun Razak Kuala Lumpur WP Malaysia 50400
- IPO Date
- Oct 31, 2025
- CIK
- 0002025774
- Website
- alps-holdings.com
- Similar Companies
- Business
- Alps Group Inc Alps Group Inc (Nasdaq: ALPS) serves as the parent company of Alps Life Sciences Inc., operating as a fully integrated biotechnology research platform and healthcare service provider specializing in predictive, preventive, and precision medicine; its core offerings encompass research and development of cellular therapies including mesenchymal stem cells, induced pluripotent stem cells, and dental pulp stem cells for regenerative medicine, anti-aging, and treatments targeting diabetes, cardiovascular, and neurodegenerative diseases; molecular genomic testing via subsidiaries such as MyGenome utilizing next-generation sequencing, digital gene platforms, microarray, and PCR for cancer, cardiac, metabolic, neurogenetic, pharmacogenetic, and wellness risk assessments; comprehensive diagnostic services including whole genome sequencing, mRNA testing, biochemistry, serology, immunology, haematology, and microbe testing; medical and wellness solutions featuring aesthetics treatments with fractional CO2 lasers, HIFU, dermal fillers, and PRP; cosmetic surgery for eye, nasal, lip, and breast enhancements; health screenings with oxidative stress, tumor markers, dietitian consultations, and nutritional balancing; alongside health consulting, genomic DNA and WGS wholesale services, Célebre Pro Medic stem cell supplements, and innovative financial products for healthcare-linked wealth management and affordable vaccines via immune informatics and genetic engineering. The company maintains a cGMP-certified facility for cell and gene therapy approved by Malaysia's Ministry of Health, alongside an MS ISO 15189:2022-accredited molecular laboratory, targeting healthcare providers, corporations, governments, institutions, high-net-worth individuals, and international medical tourism clients primarily in Asia with global aspirations through its BioValley initiative. Founded in 2017 and headquartered in Kuala Lumpur, Malaysia, Alps Group Inc recently completed a transformative business combination with Globalink Investment Inc on October 31, 2025, enabling Nasdaq listing under ticker ALPS and raising approximately US$3.1 million via PIPE investment to fuel growth and working capital, while advancing its international network for stem cell production, R&D hubs, and ecosystem collaboration in biotechnology research, manufacturing, and clinical applications.
Small Cap Quality Over Size: Why ALPS OUSM Deserves a Look
Alps Group Inc Launches Patient-Derived Organoid Program to Advance Personalized Cancer Care in Southeast Asia
ETFs for Investors Seeking Balance Amid Ceasefire Optimism
Alps Group Inc Expands MyGenome Accreditation to Include Whole Genome Sequencing Under MS ISO 15189:2022
Love the AI Story but Hate the Concentration Risk? Consider ETFs
ALPS EQL Swaps SPDR ETFs for New VettaFi Index
Tech-Heavy & Anxious? Pick ETFs to Diversify Beyond the AI Bet
Alps Group Inc Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
AI and Earnings Lift S&P 500 Outlook: ETFs for Long-Term Growth
Alps Group Appoints Former Ernst & Young Partner to Board of Directors, Strengthening Governance and Capital Markets Oversight
Alps Announces Closing of Business Combination with Globalink Investment Inc.
Why Is Alpine Summit Energy (ALPS) Stock Down 4% Today?
Alpine Commences Voluntary Chapter 11 Process